Alpha Tau Medical Ltd. (DRTS)
| Market Cap | 642.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.63M |
| Shares Out | 88.01M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 471,381 |
| Open | 7.85 |
| Previous Close | 7.91 |
| Day's Range | 7.30 - 7.90 |
| 52-Week Range | 2.50 - 8.60 |
| Beta | 1.05 |
| Analysts | Strong Buy |
| Price Target | 8.67 (+18.77%) |
| Earnings Date | May 18, 2026 |
About DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DRTS stock is "Strong Buy." The 12-month stock price target is $8.67, which is an increase of 18.77% from the latest price.
News
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
- Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world's largest and most prestigious medical oncology conference - - Pooled analysis combines safety and ef...
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxan
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced th...
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced th...
Alpha Tau Medical Transcript: Sidoti March Small-Cap Virtual Conference
Significant regulatory and clinical progress includes Japan's approval for head and neck cancer, near-completion of pivotal U.S. skin cancer trials, and promising pancreatic and GBM study updates. Strategic partnerships and a strong financial position support a transformative year ahead.
Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd . (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced th...
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and...
HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
TOKYO--(BUSINESS WIRE)-- #cancer--Japan approves Alpha DaRT for head & neck cancer, becoming the first market outside Israel.
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, ...
Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing
Inspired Healthcare Capital (IHC) filed for bankruptcy on Feb. 2, 2026, raising questions for investors in its DST and alternative investment offerings.
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in can...
Alpha Tau Medical Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Alpha DaRT technology is advancing through pivotal clinical trials in skin, pancreatic, and brain cancers, with strong early data and a modular FDA submission strategy. Manufacturing scale-up is underway, and commercialization plans target direct U.S. sales and global partnerships.
Alpha Tau Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
A novel alpha particle-based cancer therapy is advancing through multiple pivotal and pilot trials, showing strong efficacy and safety across tumor types. Key regulatory milestones and manufacturing expansion are underway, with major data readouts and potential approvals expected in 2024.
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation n...
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and...
Alpha Tau Medical Transcript: Sidoti's Year End Virtual Investor Conference
Recent milestones include first glioblastoma patient treated, strong interim pancreatic cancer data, and expanded U.S. trials. Regulatory progress and a robust cash position support plans for a major U.S. commercial launch by 2027, with broadening clinical applicability and growing investor interest.
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers,...
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
- Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and c...
Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options
NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Altamirano PLLC, a New York-based securities arbitration law firm, has announced an investigation into the brokerage firms that sold Inspired Healthcare Cap...
Alpha Tau Medical Transcript: Lytham Partners Fall 2025 Investor Conference
A novel alpha radiation therapy platform is advancing through pivotal and pilot trials in skin, pancreatic, and brain cancers, showing high response rates and potential immune activation. Manufacturing expansion and a strong cash position support continued progress and regulatory submissions.
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –
Alpha Tau to Participate in Five September Investor Conferences
JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, t...
Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -